Do you want to read an article? Please log in or register.
Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline
LeukemiaLymphoma
Related content
EHA® 2019
LeukemiaLymphoma
Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma
Leukemia
Lenalidomide maintenance in high risk chronic lymphocytic leukaemia: practice changing study or hypothesis generating approach?
Lancet Haematol.
Rossi D, Condoluci A.
doi: 10.1016/
Leukemia
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
Lancet Haematol.
Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR, Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.
doi: 10.1016/S2352-3026
RECOMMENDED
Leukemia
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
★ 3
Recommended by
Alexander Meisel, Faculty Member
Ann Oncol.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, Gregor M, Cymbalista F, Buske C, Hillmen P, Hallek M, Mey U, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org.
doi: 10.1016/j.annonc.2020.09.019.Visit the original publication at ncbi.nlm.nih.gov
LeukemiaLymphoma
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia
Drugs.
Deeks ED
doi: 10.1007/s40265-017-0695-3
LeukemiaLymphoma
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Leuk Lymphoma.
Fraser GAM, Chanan-Khan A, Demirkan F, Santucci Silva R, Grosicki S, Janssens A, Mayer J, Bartlett NL, Dilhuydy MS, Loscertales J, Avigdor A, Rule S, Samoilova O, Pavlovsky MA, Goy A, Mato A, Hallek M, Salman M, Tamegnon M, Sun S, Connor A, Nottage K, Schuier N, Balasubramanian S, Howes A, Cramer P
doi: 10.1080/10428194.
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial
Lancet Haematol.
Greil R, Obrtlíková P, Smolej L, Kozák T, Steurer M, Andel J, Burgstaller S, Mikušková E, Gercheva L, Nösslinger T, Papajík T, Ladická M, Girschikofsky M, Hrubiško M, Jäger U, Fridrik M, Pecherstorfer M, Králiková E, Burcoveanu C, Spasov E, Petzer A, Mihaylov G, Raynov J, Oexle H, Zabernigg A, Flochová E, Palášthy S, Stehlíková O, Doubek M, Altenhofer P, Pleyer L, Melchardt T, Klingler A, Mayer J, Egle A
doi: 10.1016/
Leukemia
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
Lancet Oncol.
Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P
doi: 10.1016/
LeukemiaLymphoma
Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length
Leuk Lymphoma.
Ammann EM, Shanafelt TD, Wright KB, McDowell BD, Link BK, Chrischilles EA
doi: 10.1080/